The overall 5-year relative survival rate for ovarian cancer depends heavily on how far the disease has spread at the time of diagnosis. When caught early and still confined to the ovaries, the 5-year survival rate is about 92%. When the cancer has already spread to distant organs, that number drops to roughly 31.5%. These figures come from federal cancer surveillance data covering diagnoses between 2016 and 2022.
Survival Rates by Stage at Diagnosis
Ovarian cancer survival is grouped into three broad categories based on how far the cancer has spread:
- Localized (confined to the ovaries): 91.9% five-year survival
- Regional (spread to nearby tissues or lymph nodes): 70.1%
- Distant (spread to organs like the liver or lungs): 31.5%
The challenge is that ovarian cancer rarely causes obvious symptoms in its early stages. Bloating, pelvic pain, and feeling full quickly can all be mistaken for digestive issues. As a result, the majority of cases are diagnosed at the distant stage, which largely explains why the overall survival statistics look worse than many other cancers.
How the Type of Tumor Affects Outlook
Not all ovarian cancers behave the same way. The tumor type plays a major role in prognosis.
Invasive epithelial ovarian cancer is by far the most common form, accounting for about 90% of cases. Its survival rates closely mirror the overall numbers: 92% for localized, 71% for regional, and 32% for distant disease. Within this category, the most aggressive subtype is high-grade serous carcinoma. A large-scale analysis found that this subtype has a median overall survival of 3.8 years and a 5-year survival rate of just 38.4%.
Germ cell tumors and stromal tumors are far less common but carry a much better prognosis. Germ cell tumors have a 98% five-year survival rate when localized and still reach 76% even at the distant stage. Stromal tumors are similar: 96% when localized, 75% when distant. These types tend to respond well to treatment and are more often diagnosed in younger patients.
Age Makes a Significant Difference
Younger women diagnosed with ovarian cancer consistently do better than older women. Five-year survival rates break down like this by age group:
- Under 50: 72.8%
- 50 to 64: 54.7%
- Over 64: 34%
Several factors drive this gap. Younger women are more likely to be diagnosed at an earlier stage, and they tend to tolerate aggressive treatment better. There’s also a treatment access problem at the other end of the spectrum: more than 40% of women aged 85 and older receive no definitive treatment after diagnosis, according to data from the National Library of Medicine.
Recurrence and What It Means for Long-Term Survival
One of the hardest realities of ovarian cancer is its tendency to come back. In a complete 10-year study of patients with advanced disease, 83% experienced a recurrence. The median time to recurrence was 18 months, meaning most relapses happened within a year or so of finishing initial treatment.
Still, long-term survival is possible even in advanced cases. In that same study, 8.5% of patients were alive more than 10 years after diagnosis. And the longer someone goes without recurrence, the better their odds become. Patients who had already survived one year had a 33% chance of reaching the five-year mark. For those who had already survived five years, the probability of making it to year ten jumped to 57%.
What happens during initial surgery matters a great deal for recurrence risk. Patients whose surgeons were able to remove all visible tumor had substantially lower recurrence rates than those with residual disease left behind.
10-Year Survival by Stage and Age
Five-year survival gets the most attention, but many patients and families want to know what the longer picture looks like. The conventional 10-year overall survival rate for ovarian cancer across all stages is 29%. Broken down by stage, the numbers are stark: 75% for stage I/II disease, 22% for stage III, and roughly 7% for stage IV.
For patients who have already reached the five-year mark, the outlook improves considerably. Among five-year survivors under 65, the probability of reaching 10 years is 65% overall, 89% for early-stage disease, and 58% for stage III. For those 65 and older who have survived five years, the 10-year probability is 48% overall and 78% for early-stage disease. These “conditional survival” numbers are often more useful than the initial statistics, because they reflect the reality that the risk of dying from ovarian cancer decreases with every year of survival.
How Newer Treatments Have Shifted the Numbers
Treatment advances over the past decade, particularly a class of drugs called PARP inhibitors used as maintenance therapy after chemotherapy, have begun to shift survival outcomes. Population-level data shows that patients diagnosed in the era after PARP inhibitors became available had a modest but statistically significant improvement in overall survival compared to those diagnosed before, with a 7% reduction in the risk of death. Median overall survival moved from 37 months to 38 months across the broad population, though individual benefit varies widely based on tumor genetics and how well the cancer responds to initial treatment.
These drugs work by blocking a DNA repair mechanism that certain cancer cells rely on, making them especially effective in tumors with specific genetic mutations. For patients whose tumors carry those mutations, the benefit can be substantially larger than the population average suggests.